Children's National Research Institute
This is a research study to find out if treatment with transdermal estradiol patches started between 8 to 11.5 years is safe in girls with Turner syndrome who have ovarian failure and to see whether it may improve performance on two tests of working speed and short-term memory.
The investigators hypothesize that ultra-low dose TDE will improve neurocognitive measures without a negative impact on growth and pubertal maturation in the peripubertal period. To test this hypothesis, investigators will conduct a prospective single center pilot trial and recruit up to 15 girls with TS and POI (FSH\>10 in the past year), ages 8 to \<11.5 years who will receive ultra-low dose TDE \[defined as 1/8th patch of 0.025mg/24h applied weekly (delivering 3.125mcg/24h)\] for 6 months to address the following objectives. Primary: Study the effect of ultra-low dose TDE therapy on proces…
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Female, aged 8 years up to 11 y and 180 days with karyotype confirmed Turner syndrome 4. FSH result\> 10miu/mL in the past 12 months. Since variability in FSH is not uncommon, a single measure of FSH \>10mIU/mL in the past calendar year will be deemed sufficient for inclusion into the study even if repeat measures may be under 10mIU/mL. 5. Ability to take the transdermal estradiol medication and be willing to adh…
Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch will be applied and changed weekly for 6 months
Arctuva estimate
Verify or correct the compensation shown for this listing.